Overview

A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors

Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
to assess the safety, tolerability，PK and efficacy profile of two doses (600mg,800mg,BID) of Icaritin in advanced solid tumor patients in China
Phase:
Phase 1
Details
Lead Sponsor:
Chinese Academy of Medical Sciences
Collaborator:
Beijing Shenogen Biomedical Co., Ltd